articleThe LancetSep 15, 2014GREEN OA

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Imperial College London · Hôpital Privé Jacques Cartier · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

560
total citations
FWCI
110.55
Percentile
100%
References
39
Citations per year

Authors

17

Topics & keywords

Keywords
  • Medicine
  • Everolimus
  • Myocardial infarction
  • Cardiology
  • Internal medicine
  • Clinical endpoint
  • Stent
  • Coronary artery disease
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.